Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US.

Crane HM, Nance RM, Heckbert SR, Ritchings C, Rosenblatt L, Budoff M, Wood BR, Tirschwell DL, Kim HN, Mathews WC, Geng E, Moore RD, Hunt PW, Eron JJ, Burkholder GA, Drozd DR, Chow FC, Becker KJ, Zunt JR, Ho EL, Kalani R, Huffer A, Whitney BM, Saag MS, Kitahata MM, Delaney JA.

J Acquir Immune Defic Syndr. 2019 May 16. doi: 10.1097/QAI.0000000000002071. [Epub ahead of print]

PMID:
31135582
2.

Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients.

Dhamane AD, Baker CL, Rajpura J, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Lin J.

Curr Med Res Opin. 2019 Jun 5:1-8. doi: 10.1080/03007995.2019.1623187. [Epub ahead of print]

PMID:
31120309
3.

Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.

Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH.

J Am Geriatr Soc. 2019 May 21. doi: 10.1111/jgs.15956. [Epub ahead of print]

PMID:
31112292
4.

Eight-year-old Boy with New-onset Seizure.

Rosenblatt L, Khoujah D, Dezman ZDW, Bontempo LJ.

Clin Pract Cases Emerg Med. 2019 Apr 12;3(2):89-94. doi: 10.5811/cpcem.2019.4.42547. eCollection 2019 May.

5.

Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.

Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL.

J Thromb Thrombolysis. 2019 Mar 28. doi: 10.1007/s11239-019-01838-5. [Epub ahead of print]

PMID:
30924051
6.

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure.

Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A.

PLoS One. 2019 Mar 25;14(3):e0213614. doi: 10.1371/journal.pone.0213614. eCollection 2019.

7.

Pilot Study to Evaluate the Adjunct Use of a Povidone-Iodine Topical Antiseptic in Patients with Soft Tissue Abscesses.

Olson AS, Rosenblatt L, Salerno N, Odette J, Ren R, Emanuel T, Michalek J, Liu Q, Du L, Jahangir K, Schmitz GR.

J Emerg Med. 2019 Apr;56(4):405-412. doi: 10.1016/j.jemermed.2018.12.026. Epub 2019 Feb 27.

PMID:
30826080
8.

Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Trocio J, Rosen VM, Gupta A, Dina O, Vo L, Hlavacek P, Rosenblatt L.

Clinicoecon Outcomes Res. 2018 Dec 19;11:23-49. doi: 10.2147/CEOR.S179080. eCollection 2019.

9.

Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States.

Baker CL, Dhamane AD, Mardekian J, Dina O, Russ C, Rosenblatt L, Lingohr-Smith M, Menges B, Lin J, Nadkarni A.

Adv Ther. 2019 Jan;36(1):162-174. doi: 10.1007/s12325-018-0840-8. Epub 2018 Nov 29.

10.

Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.

Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A.

Clin Appl Thromb Hemost. 2018 Nov 15:1076029618800806. doi: 10.1177/1076029618800806. [Epub ahead of print]

PMID:
30433823
11.

Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.

Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T.

J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127. doi: 10.18553/jmcp.2018.17488. Epub 2018 Sep 13.

12.

A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population.

Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L.

J Manag Care Spec Pharm. 2018 Sep;24(9):911-920. doi: 10.18553/jmcp.2018.24.9.911.

13.

Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Nance RM, Crane HM, Ritchings C, Rosenblatt L, Budoff M, Heckbert SR, Drozd DR, Mathews WC, Geng E, Hunt PW, Feinstein MJ, Moore RD, Hsue P, Eron JJ, Burkholder GA, Rodriguez B, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):916-921. doi: 10.1089/AID.2018.0053. Epub 2018 Aug 21.

PMID:
29984593
14.

Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry.

Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S, Kremer JM, Harrold LR.

J Rheumatol. 2018 Oct;45(10):1353-1360. doi: 10.3899/jrheum.171050. Epub 2018 Jul 1.

15.

Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.

LaFleur J, Bress AP, Myers J, Rosenblatt L, Crook J, Knippenberg K, Bedimo R, Tebas P, Nyman H, Esker S.

Infect Dis Ther. 2018 Jun;7(2):293-308. doi: 10.1007/s40121-018-0194-1. Epub 2018 Feb 28.

16.

Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.

LaFleur J, Bress AP, Esker S, Knippenberg K, Crook J, Nyman H, Bedimo R, Tebas P, Rosenblatt L.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):325-330. doi: 10.1097/QAI.0000000000001608.

PMID:
29210830
17.

Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

J Rheumatol. 2018 Jan;45(1):32-39. doi: 10.3899/jrheum.170007. Epub 2017 Nov 1.

18.

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.

LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C.

AIDS. 2017 Sep 24;31(15):2095-2106. doi: 10.1097/QAD.0000000000001594.

19.

Economic Outcomes of First-Line Regimen Switching Among Stable Patients with HIV.

Rosenblatt L, Buikema AR, Seare J, Bengtson LGS, Johnson J, Cao F, Villasis-Keever A.

J Manag Care Spec Pharm. 2017 Jul;23(7):725-734. doi: 10.18553/jmcp.2017.16403. Epub 2017 Jun 5.

20.

Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.

Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L.

Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11.

PMID:
28635338
21.

Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice.

Drozd DR, Saag MS, Westfall AO, Mathews WC, Haubrich R, Boswell SL, Cole SR, Porter D, Kitahata MM, Juday T, Rosenblatt L; CFAR Network of Integrated Clinical Systems (CNICS).

Medicine (Baltimore). 2017 Apr;96(14):e6275. doi: 10.1097/MD.0000000000006275.

22.

A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?

Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM.

Clin Rheumatol. 2017 Jun;36(6):1215-1220. doi: 10.1007/s10067-017-3588-7. Epub 2017 Mar 1.

23.

Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.

Rosenblatt L, Broder MS, Bentley TGK, Chang E, Reddy SR, Papoyan E, Myers J.

AIDS Care. 2017 Aug;29(8):1067-1073. doi: 10.1080/09540121.2017.1280123. Epub 2017 Feb 1.

PMID:
28147708
24.

Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.

Goolsby Hunter A, Rosenblatt L, Patel C, Blauer-Peterson C, Anduze-Faris B.

Curr Med Res Opin. 2017 May;33(5):829-836. doi: 10.1080/03007995.2017.1288613. Epub 2017 Feb 10.

PMID:
28128648
25.

Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.

Nkhoma ET, Rosenblatt L, Myers J, Villasis-Keever A, Coumbis J.

PLoS One. 2016 Dec 12;11(12):e0166982. doi: 10.1371/journal.pone.0166982. eCollection 2016.

26.
27.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

Gallant J, Moyle G, Berenguer J, Shalit P, Cao H, Liu YP, Myers J, Rosenblatt L, Yang L, Szwarcberg J.

Curr HIV Res. 2017;15(3):216-224. doi: 10.2174/1570162X14666161021102728.

28.

Erratum to: Risk of cardiovascular events among patients with HIV treated with atazanavircontaining regimens: a retrospective cohort study.

Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK, Ritchings C, Johnston SS.

BMC Infect Dis. 2016 Oct 7;16(1):547. No abstract available.

29.

Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review.

Chow D, Shikuma C, Ritchings C, Guo M, Rosenblatt L.

Infect Dis Ther. 2016 Dec;5(4):473-489. Epub 2016 Sep 27. Review.

30.

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.

Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK, Ritchings C, Johnston SS.

BMC Infect Dis. 2016 Sep 19;16:492. doi: 10.1186/s12879-016-1827-1. Erratum in: BMC Infect Dis. 2016 Oct 7;16(1):547.

31.

Axon Counts Yield Multiple Options for Triceps Fascicular Nerve to Axillary Nerve Transfer.

Khair MM, Schreiber JJ, Rosenblatt L, Byun DJ, Lee SK, Wolfe SW.

J Hand Surg Am. 2016 Nov;41(11):e405-e410. doi: 10.1016/j.jhsa.2016.07.110. Epub 2016 Aug 28.

PMID:
27577524
32.

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens.

Rosenblatt L, Farr AM, Johnston SS, Nkhoma ET.

Open Forum Infect Dis. 2016 Mar 30;3(2):ofw061. doi: 10.1093/ofid/ofw061. eCollection 2016 Mar.

33.

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.

Nkhoma ET, Coumbis J, Farr AM, Johnston SS, Chu BC, Rosenblatt LC, Seekins D, Villasis-Keever A.

Medicine (Baltimore). 2016 Jan;95(3):e2480. doi: 10.1097/MD.0000000000002480.

34.

Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.

Farr AM, Johnston SS, Ritchings C, Brouillette M, Rosenblatt L.

J Med Econ. 2016;19(4):386-96. doi: 10.3111/13696998.2015.1128942. Epub 2015 Dec 29.

PMID:
26640980
35.

The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.

Snider JT, Goldman DP, Rosenblatt L, Seekins D, Juday T, Sanchez Y, Wu Y, Peneva D, Romley JA.

Med Care Res Rev. 2016 Jun;73(3):329-48. doi: 10.1177/1077558715614479. Epub 2015 Nov 3.

PMID:
26537525
36.

Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice.

Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH.

J Clin Gastroenterol. 2016 Feb;50(2):169-74. doi: 10.1097/MCG.0000000000000345.

PMID:
26018133
37.

Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.

Cure S, Bianic F, Espinas C, Hardy H, Rosenblatt L, Juday T.

PLoS One. 2015 May 4;10(5):e0124666. doi: 10.1371/journal.pone.0124666. eCollection 2015. Review.

38.

Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Med Econ. 2015;18(10):763-76. doi: 10.3111/13696998.2015.1046878.

PMID:
25934146
39.

Optimal axon counts for brachial plexus nerve transfers to restore elbow flexion.

Schreiber JJ, Byun DJ, Khair MM, Rosenblatt L, Lee SK, Wolfe SW.

Plast Reconstr Surg. 2015 Jan;135(1):135e-41e. doi: 10.1097/PRS.0000000000000795.

PMID:
25539320
40.

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.

Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19605. doi: 10.7448/IAS.17.4.19605. eCollection 2014.

41.

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting.

Farr AM, Johnston SS, Ritchings C, Brouillette M, Rosenblatt L.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19538. doi: 10.7448/IAS.17.4.19538. eCollection 2014.

42.

The prospect of a generation free of HIV may be within reach if the right policy decisions are made.

Goldman DP, Juday T, Linthicum MT, Rosenblatt L, Seekins D.

Health Aff (Millwood). 2014 Mar;33(3):428-33. doi: 10.1377/hlthaff.2013.1280.

PMID:
24590941
43.

Data-driven decision-making tools to improve public resource allocation for care and prevention of HIV/AIDS.

Ryan GW, Bloom EW, Lowsky DJ, Linthicum MT, Juday T, Rosenblatt L, Kulkarni S, Goldman DP, Sayles JN.

Health Aff (Millwood). 2014 Mar;33(3):410-7. doi: 10.1377/hlthaff.2013.1155.

PMID:
24590938
44.

HIV care providers emphasize the importance of the Ryan White Program for access to and quality of care.

Sood N, Juday T, Vanderpuye-Orgle J, Rosenblatt L, Romley JA, Peneva D, Goldman DP.

Health Aff (Millwood). 2014 Mar;33(3):394-400. doi: 10.1377/hlthaff.2013.1297.

PMID:
24590936
45.

Nearly 60,000 uninsured and low-income people with HIV/AIDS live in states that are not expanding Medicaid.

Snider JT, Juday T, Romley JA, Seekins D, Rosenblatt L, Sanchez Y, Goldman DP.

Health Aff (Millwood). 2014 Mar;33(3):386-93. doi: 10.1377/hlthaff.2013.1453. Erratum in: Health Aff (Millwood). 2014 Apr;33(4):724.

PMID:
24590935
46.

Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.

Meissner B, Trivedi D, You M, Rosenblatt L.

J Med Econ. 2014 Apr;17(4):259-65. doi: 10.3111/13696998.2014.893241. Epub 2014 Feb 27.

PMID:
24575891
47.

Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis.

Hochberg MC, Berry S, Broglio K, Rosenblatt L, Nadkarni A, Trivedi D, Hebden T.

Curr Med Res Opin. 2013 Oct;29(10):1213-22. doi: 10.1185/03007995.2013.813839. Epub 2013 Jul 25. Review.

PMID:
23745516
48.

Current methods and biomechanics of extensor tendon repairs.

Dy CJ, Rosenblatt L, Lee SK.

Hand Clin. 2013 May;29(2):261-8. doi: 10.1016/j.hcl.2013.02.008. Epub 2013 Mar 16. Review.

PMID:
23660062
49.

Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective.

Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T.

Clinicoecon Outcomes Res. 2012;4:227-35. doi: 10.2147/CEOR.S31784. Epub 2012 Aug 23.

50.

The economic consequences of rheumatoid arthritis: analysis of Medical Expenditure Panel Survey 2004, 2005, and 2006 data.

Simons WR, Rosenblatt LC, Trivedi DN.

J Occup Environ Med. 2012 Jan;54(1):48-55. doi: 10.1097/JOM.0b013e31823c13e7.

PMID:
22227873

Supplemental Content

Loading ...
Support Center